bioRxivNeurosciencePreprint
AAV delivery of GBA1 suppresses alpha-synuclein accumulation in Parkinson's disease models and restores motor dysfunction in a Gaucher's disease model
Takuro OkaiiD, Sho Sato, Mugdha DeshpandeiD, Shin-ichi MatsumotoiD, Miyu NakayamaiD, Syunsuke YamamotoiD, Bettina Strack-Logue, Takeshi HiokiiD, Maiko Tanaka, Gabriele ProetzeliD
Abstract
Biallelic mutations in the glucosylceramidase beta 1 (GBA1) gene are the underlying genetic cause of Gauchers disease (GD), resulting in a deficient lysosomal hydrolase and subsequent accumulation of glycosphingolipids. More recently, GBA1 mutations have been identified as the most prevalent genetic risk factor for Parkinsons disease (PD), associated with more pronounced symptoms characterized by earlier onset and accelerated cognitive decline. In these GBA-associated PD patients the -synuclein pathology is more prominent, and recent data suggest a link between -synucleinopathies and GBA1 mutations. Here, we explored the effect of GBA1 gene supplementation on the GD phenotypes and -synuclein pathology by using the adeno-associated virus (AAV) system. We have compared two AAV serotypes, AAV5 and AAV9, and two different ubiquitous promoters, and demonstrate that both promoters work efficiently albeit not the same in vitro and in vivo. GBA1 overexpression reduces the accumulation of glucosylsphingosine (GlcSph) and restores motor dysfunction in a GD mouse model. We further demonstrate that GBA1 overexpression can dissolve phospho--synuclein aggregation induced by the addition of -synuclein pre-formed fibril (PFF) in a mouse primary neuron model suggesting the direct effect of {beta}-Glucocerebrosidase (GCase) on -synuclein accumulation. In vivo, we show that GCase inhibition can induce insoluble high-molecular-weight -synuclein aggregation and that delivery of GBA1 achieves robust reduction of the -synuclein aggregates in the mouse brain. In summary, GCase expression not only reduces GlcSph, but also restores GD motor dysfunction and removes -synuclein aggregates which are the hallmark for PD and -synucleinopathies. AAV delivery of GBA1 is a powerful approach to restore glucocerebrosidase function and to resolve misfolded -synuclein protein, with applications for GD and PD.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neuronopathic GBA1 L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
Casey L. Mahoney-Crane, Megha Viswanathan, … Laura A. Volpicelli‐Daley·Journal of NeurosciencePeer-reviewed·Dec 7, 2022
- AAV gene therapy for GBA-PD and Gaucher Disease
Swathi Ayloo, Jae Cheon Ryu, … Shyam S. Ramachandran·bioRxiv·Jun 17, 2025
- A human GBA-L444P transgene drives early and persistent dopamine neurotransmission deficits and alpha-synuclein pathology in a mouse model of early Parkinson's disease
Natalie Connor‐Robson, Tara Diviney, … Richard Wade‐Martins·bioRxiv·May 27, 2026
- A double-hit in vivo model of GBA1 viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration
Alexia Polissidis, Effrosyni Koronaiou, … Leonidas Stefanis·Neurobiology of DiseasePeer-reviewed·Jan 4, 2022
- GBA1 deficiency differentially affects endolysosomal trafficking in neurons versus astrocytes
Anna J. Park, Sarah Fish, … Marie Y. Davis·bioRxiv·Jan 13, 2026
- Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson's disease and Dementia with Lewy bodies
D. J. Vidyadhara, David C. Bäckström, … Sreeganga S. Chandra·bioRxiv·Oct 23, 2024